IL17RB and plasma cell myeloma: Sequencing studies in relapsed multiple myeloma and functional screens identified acquired genetic alterations in members of the CRBN-CRL4 E3 ligase complex that completely abrogate lenalidomide and pomalidomide activity as an IMiD-specific resistance mechanism in 10–20% of relapsed patients9–13.